Partex Logo
  • Home
  • Who We Are
    • Vision
    • Team Overview
    • Careers
  • Our Businesses
    • Therapeutics
    • Exchange
    • Labs
    • Real-World Data
  • Platform
  • News & Media
    • Awards
    • News
    • Events
    • Whitepapers & Publications
  • Contact Us
Partex Logo© 2026 Partex NVPrivacy PolicyImprint

白皮书 出版物

Artificial Intelligence Opportunities to Accelerate Rare Disease Innovation

Whitepaper

Published on: 04-March-2026

Strategic AI/ML Interventions Aligned to the 2026 Rare Disease Strategic Agenda from FDA Rare Disease Innovation Hub.
A Deep Dive into Obesity: How 2026 Clinical Readouts Are Redefining the Weight Loss Landscape

Whitepaper

Published on: 17-February-2026

2026 is redefining obesity treatment—moving from weight loss alone to oral therapies, muscle preservation, and long-term metabolic health.
2026 Data Watchlist: Late-Stage Clinical Trial Readouts That Matter

Whitepaper

Published on: 30-January-2026

2026 will be a pivotal year for drug development—read our latest white paper to explore the late-stage clinical trial readouts set to reshape medicine and markets.
China as a Global Licensing Hub: In- and Out-Licensing  Deals in the Biopharmaceutical Industry

Whitepaper

Published on: 23-January-2026

China is no longer just in the pharma race — it’s helping define where global innovation comes from.
2026: From Managing Symptoms to Engineering Cures

Whitepaper

Published on: 31-December-2025

2026 marks biotech’s shift to precision cures—removing disease proteins, retraining biology, and targeting delivery to unlock safer, more durable therapies and long-term clinical leadership.
Rare Disease Therapeutics: 2025 Deal Trends and Outlook

Whitepaper

Published on: 19-December-2025

2025 emerged as a pivotal year for rare-disease dealmaking, driven by advanced biologics, strategic licensing, and strong unmet medical needs.
Insights from key acquisitions by top 10 Big Pharma (2024 - DEC 2025)

Whitepaper

Published on: 15-December-2025

Big Pharma M&As are driven by premium platform technologies, neurology, oncology and obesity bets and near-term readouts that will validate the deals.
2025 Oncology Licensing Deal Landscape Analysis

Whitepaper

Published on: 11-December-2025

Oncology remains the undisputed leader in global dealmaking for 2025, fueled by relentless demand for differentiated therapies and next-generation modalities
INNOPLEXUS’ CTP MODEL

Whitepaper

Published on: 06-April-2022

Innoplexus’ CTP model forecasts the outcome of clinical studies and may serve as an early indicator for future stock movements.
EMERGENCE OF CHIMERIC ANTIGEN

Whitepaper

Published on: 06-April-2022

Emergence of chimeric antigen receptor-t (CAR-T) cell therapies for cancer treatment
GENE THERAPY

Whitepaper

Published on: 06-April-2022

Gene therapy promises to hold the cure to a number of diseases which, until now, have been considered incurable. Read our recent whitepaper

我们不仅发现药物

我们管理它们的未来

与我们联系,探索许可、合作伙伴关系,或AI如何重塑您的药物管线

联系我们